7a-Thiomethyl spironolactone
CAS: 38753-77-4
Ref. 3D-FT28228
| 1mg | Discontinued | ||
| 2mg | Discontinued | ||
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 500µg | Discontinued |
Product Information
- 17a-Hydroxy-7a-(methylthio)-3-oxo-pregn-4-ene-21-carboxylic acid gamma-lactoneSC 265197a-Thiomethylspirolactone
- Pregn-4-ene-21-carboxylic acid, 17-hydroxy-7-(methylthio)-3-oxo-, γ-lactone, (7α,17α)-
- Spiro[17H-cyclopenta[a]phenanthrene-17,2′(5′H)-furan], pregn-4-ene-21-carboxylic acid deriv.
- SC 26519
- 3-(3-Oxo-7α-methylthio-17β-hydroxy-4-androsten-17α-yl)propionic acid γ-lactone
- 7α-(Methylthio)spironolactone
Spironolactone is an antihypertensive drug that acts as a mineralocorticoid receptor antagonist, competitively binding to the receptor and blocking its activity. It is used in the treatment of hypertension, congestive heart failure, and edema. Spironolactone binds to α1-acid glycoprotein (AAG) in the blood, which is eliminated at a slower rate than other proteins. This results in a longer period of time for spironolactone to be present in the bloodstream and exert its effects on target tissue. The bioavailability of spironolactone has been shown to be dependent on the dose administered and can be determined by measuring this drug's plasma concentration over time. The linear model has been shown to provide accurate estimates of AAG binding activities in serum samples from human subjects who have taken spironolactone (100 mg) or placebo. Spironolactone binds with high affinity to mineralocorticoid receptors present
